Last reviewed · How we verify
AJG555
AJG555 is a guanylate cyclase-C (GC-C) agonist that increases intracellular cGMP to promote fluid secretion and accelerate intestinal transit.
AJG555 is a guanylate cyclase-C (GC-C) agonist that increases intracellular cGMP to promote fluid secretion and accelerate intestinal transit. Used for Irritable bowel syndrome with constipation (IBS-C), Chronic idiopathic constipation (CIC).
At a glance
| Generic name | AJG555 |
|---|---|
| Sponsor | EA Pharma Co., Ltd. |
| Drug class | Guanylate cyclase-C agonist |
| Target | GC-C (guanylate cyclase-C) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
By activating guanylate cyclase-C receptors on intestinal epithelial cells, AJG555 increases cyclic GMP levels, which triggers chloride and bicarbonate secretion into the intestinal lumen and enhances intestinal motility. This mechanism promotes stool passage and is designed to treat functional gastrointestinal disorders characterized by constipation or reduced intestinal transit.
Approved indications
- Irritable bowel syndrome with constipation (IBS-C)
- Chronic idiopathic constipation (CIC)
Common side effects
- Diarrhea
- Abdominal pain
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AJG555 CI brief — competitive landscape report
- AJG555 updates RSS · CI watch RSS
- EA Pharma Co., Ltd. portfolio CI